Exelon (EXC) director receives 5 deferred phantom share equivalents in cash-settled plan
Rhea-AI Filing Summary
Lillie Charisse R reported acquisition or exercise transactions in this Form 4 filing.
Exelon Corp director Charisse R. Lillie received a grant of 5 deferred phantom share equivalents tied to Exelon common stock. These were awarded at a reference price of $46.62 per equivalent and increase her deferred phantom share balance to 3,896 equivalents.
The phantom share equivalents are held in an Exelon stock fund account within a multi-fund, non-qualified deferred compensation plan and will be settled in cash on a 1-for-1 basis after her service on the board ends. The balance includes 35 additional equivalents that accrued automatically through dividend reinvestment, highlighting this as compensation and deferral activity rather than open-market trading.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred phantom share equivalents | 5 | $46.62 | $233.10 |
Footnotes (2)
- F1. Phantom share equivalents held in the reporting person's Exelon stock fund account that is part of a multi-fund, non-qualified deferred compensation plan. Phantom share equivalents will be settled for cash on a 1 for 1 basis upon the termination of the reporting person's service to the board of directors.
- F2. Balance includes 35 additional phantom share equivalents accrued to the account through automatic dividend reinvestment.
Key Figures
Key Terms
non-qualified deferred compensation plan financial
automatic dividend reinvestment financial
FAQ
What did Exelon (EXC) director Charisse R. Lillie report in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.